vedolizumab (Entyvio)
Jump to navigation
Jump to search
Indications
- inflammatory bowel disease (FDA-approved May 2014)[2]
- induction response is higher for ulcerative colitis than for Crohn's disease
- maintenance of remission in both is ~40% at 1 year[1]
Contraindications
- hypersensitivity to vedolizumab or any of its components
- poor activity against inflammatory bowel-associated arthritis
* Pregnancy:
- no reported birth defects, miscarriage or adverse maternal or fetal outcomes attributable to vedolizumab
- no fetal harm in animal studies[4]
Laboratory
Mechanism of action
* reduces hospital admissions for inflammatory bowel disease[3]
* reduces frequency of flares & need for glucocorticoids[3]
More general terms
References
- ↑ 1.0 1.1 Feagan BG et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013 Aug 22; 369:699 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23964933 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1215734
Sandborn WJ et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013 Aug 22; 369:711 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23964933 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1215739 - ↑ 2.0 2.1 FDA News Release. May 20, 2014 FDA approves Entyvio to treat ulcerative colitis and Crohn's disease. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm398065.htm
- ↑ 3.0 3.1 3.2 Walsh N Vedolizumab Tx Cuts Admissions in IBD - Rate of flares and need for corticosteroids also decreased. MedPage Today. Dec 9, 2016 http://www.medpagetoday.com/MeetingCoverage/AIBD/61970
- ↑ 4.0 4.1 Highlights of Prescribing Information Entyvio (vedolizumab) for injection intravenous use https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125476Orig1s046lbl.pdf
- ↑ 5.0 5.1 NEJM Knowledge+ Complex Medical Care